Projektergebnisse
CORDIS bietet Links zu öffentlichen Ergebnissen und Veröffentlichungen von HORIZONT-Projekten.
Links zu Ergebnissen und Veröffentlichungen von RP7-Projekten sowie Links zu einigen Typen spezifischer Ergebnisse wie Datensätzen und Software werden dynamisch von OpenAIRE abgerufen.
Leistungen
Report on the activities, outcomes and planned follow up to assess and address the ELMs portfolio needs. This includes contribution to the regulatory debate by engaging early on and continuously with regulatory bodies. Any confidential information related to these activities will be included in the technical periodic report
Portfolio’s Dissemination and communication activities RP1 (öffnet in neuem Fenster)The report includes a description of the activities, the outcomes and any planned follow up.
ELSA activities in RP2 (öffnet in neuem Fenster)Report on the activities, outcomes and planned follow up to address ethical, legal and social aspects (ELSA). These activities include engagement with strategic partners (including the public), and dissemination of best practices and guidelines when applicablewith the ELMs field. Any confidential information related to these activities will be included in the technical periodic report.
Final definition of an ELSA, regulatory and standardization actionable strategy (öffnet in neuem Fenster)Contribution to the regulatory debate in RP1 (öffnet in neuem Fenster)
Report on the activities, outcomes and planned follow up to assess and address the ELMs portfolio needs. This includes contribution to the regulatory debate by engaging early on and continuously with regulatory bodies. Any confidential information related to these activities will be included in the technical periodic report.
Plan for Dissemination and exploitation including communication activities (öffnet in neuem Fenster)Deliver a dissemination and exploitation plan including communication activities.
Contribution to the regulatory debate in RP2 (öffnet in neuem Fenster)Report on the activities, outcomes and planned follow up to assess and address the ELMs portfolio needs. This includes contribution to the regulatory debate by engaging early on and continuously with regulatory bodies. Any confidential information related to these activities will be included in the technical periodic report.
Portfolio’s Dissemination and communication activities RP3 (öffnet in neuem Fenster)report includes a description of the activities, the outcomes and any planned follow up.
ELSA activities in RP3 (öffnet in neuem Fenster)Report on the activities, outcomes and planned follow up to address ethical, legal and social aspects (ELSA). These activities include engagement with strategic partners (including the public), and dissemination of best practices and guidelines when applicable with the ELMs field. Any confidential information related to these activities will be included in the technical periodic report
Strategic definition of the cell types needed (öffnet in neuem Fenster)Based on developmental biology knowhow research we will define the cardiac cell subtypes necessary to better mimic the tissue biology of the human heart.
ELSA activities in RP1. (öffnet in neuem Fenster)Report on the activities, outcomes and planned follow up to address ethical, legal and social aspects (ELSA). These activities include engagement with strategic partners (including the public), and dissemination of best practices and guidelines when applicable with the ELMs field. Any confidential information related to these activities will be included in the technical periodic report.
Portfolio’s Dissemination and communication activities RP2 (öffnet in neuem Fenster)The report includes a description of the activities, the outcomes and any planned follow up.
Optimized protocol for upscaling differentiation of cardiac ventricular and atrial cardiomyocytes (öffnet in neuem Fenster)To produce the ELMs we will need millions of cardiac cells, therfore we will optimized protocol for upscaling differentiation of cardiac ventricular and atrial cardiomyocytes in order to have a constant inflow of cells for the project.
Operation protocol for the scaling up process under a strict quality control process. (öffnet in neuem Fenster)To engineer the proposed ELM in a relevant size scale and further apply this technology for the massive preparation of living machines and tissue models, a scale-up of the PLMA and AMMA synthesis is required. Currently, META is working at a Pilot-Plant Scale, where the production of the final products is according to a procedure fully representative of and simulating what would be applied at the large-scale manufacturing. When working at a large-scale production, the scale-up of some equipment (bioreactors and freeze dryer) is expected. All processes will be clearly defined and to be capable of consistently manufacturing products of the required quality. Considering that the starting material is of human origin (inherent variability) there is the need to establish the minimum number of biological samples to obtain the consistency between batches of the same product. A standardized protocol for this will be developed.
Having a run website with the address of the title of the project and .eu domain. Having the logo of the project on the website
Delivery of data management plan
Platelet concentrates will be obtained from well established suppliers, such as the Hungarian National Blood Transfusion Service (Budapest, HU) and STEMCELL Technologies (Canada). PL will be produced by a freezing and thawing process. Placenta samples will be obtained from consenting mothers from Hospital da Luz (Aveiro, PT). AM will be isolated, decellularized and solubilized through established protocols. PL and AM derived proteins will be chemically modified towards photocrosslinkable materials using a protocol already patented and licensed by MT.6 7 The modified proteins will be dialyzed and freeze dried to obtain a lyophilized powder. All manufacturing processes will be clearly defined to consistently manufacture products with the required quality. Analytical tests will be performed to determine, among others: methacrylation degree, sterility and endotoxin. Written procedures will be available for sampling and testingintermediate and finished products. No batch of product is released before certification by the Quality Department that it is following its specifications. Hydrogels will be produced by dissolution of lyophilized powder at pre-defined concentrations in a solution containing the photoinitiator followed by exposure to light at different wavelengths (e.g. 375nm, 405nm). Different ratios between PLMA and AMMA will be studied in order to provide the most adequate biochemical and structural microenvironment for the cardiac cells identified by UMA and UT.
Veröffentlichungen
Autoren:
Jana Hecking, Mariel Cano-Jorge, Robert Passier, José Manuel Rivera-Arbeláez
Veröffentlicht in:
Frontiers in Bioengineering and Biotechnology, Ausgabe 13, 2026, ISSN 2296-4185
Herausgeber:
Frontiers Media SA
DOI:
10.3389/FBIOE.2025.1719533
Autoren:
Cláudia C. Oliveira, José Córdoba, John R. Pearson, Elizabeth Guruceaga, Ernesto Marín-Sedeño, María López-Moreno, Juan Antonio Guadix, Melissa García-Caballero, José M. Pérez-Pomares, Adrián Ruiz-Villalba
Veröffentlicht in:
Scientific Reports, Ausgabe 15, 2025, ISSN 2045-2322
Herausgeber:
Springer Science and Business Media LLC
DOI:
10.1038/S41598-025-24980-Y
Autoren:
Alexis Wolfel, Castro Johnbosco, Annalise Anspach, Marieke Meteling, Jos Olijve, Niklas Felix König, Jeroen Leijten
Veröffentlicht in:
Advanced Materials, ISSN 0935-9648
Herausgeber:
Wiley
DOI:
10.1002/ADMA.202501052
Autoren:
Ribeiro MC, Cano-Jorge M, Ten Den S, Snippert D, Karperien M, Kamperman T, Lajoinie G, Versluis M, Passier R
Veröffentlicht in:
Cardiovasc Res., 2026, ISSN 1755-3245
Herausgeber:
Oxford Academic
DOI:
10.1093/CVR/CVAG210
Suche nach OpenAIRE-Daten ...
Bei der Suche nach OpenAIRE-Daten ist ein Fehler aufgetreten
Es liegen keine Ergebnisse vor